As of 2024-12-14, the EV/EBITDA ratio of Pulmonx Corp (LUNG) is -3.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LUNG's latest enterprise value is 215.81 mil USD. LUNG's TTM EBITDA according to its financial statements is -54.70 mil USD. Dividing these 2 quantities gives us the above LUNG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.6x - 12.3x | 10.1x |
| Forward P/E multiples | 8.9x - 11.3x | 10.3x |
| Fair Price | (11.72) - (14.96) | (13.49) |
| Upside | -292.1% - -345.3% | -321.2% |
| Date | EV/EBITDA |
| 2024-12-10 | -4.29 |
| 2024-12-09 | -4.14 |
| 2024-12-06 | -4.16 |
| 2024-12-05 | -3.99 |
| 2024-12-04 | -4.25 |
| 2024-12-03 | -4.31 |
| 2024-12-02 | -4.26 |
| 2024-11-29 | -4.20 |
| 2024-11-27 | -4.09 |
| 2024-11-26 | -4.21 |
| 2024-11-25 | -4.31 |
| 2024-11-22 | -4.44 |
| 2024-11-21 | -4.18 |
| 2024-11-20 | -4.02 |
| 2024-11-19 | -3.87 |
| 2024-11-18 | -3.96 |
| 2024-11-15 | -4.12 |
| 2024-11-14 | -4.20 |
| 2024-11-13 | -4.39 |
| 2024-11-12 | -4.62 |
| 2024-11-11 | -4.99 |
| 2024-11-08 | -4.91 |
| 2024-11-07 | -4.86 |
| 2024-11-06 | -5.11 |
| 2024-11-05 | -4.67 |
| 2024-11-04 | -4.68 |
| 2024-11-01 | -4.07 |
| 2024-10-31 | -4.05 |
| 2024-10-30 | -4.44 |
| 2024-10-29 | -4.43 |
| 2024-10-28 | -4.02 |
| 2024-10-25 | -3.89 |
| 2024-10-24 | -3.94 |
| 2024-10-23 | -3.97 |
| 2024-10-22 | -3.97 |
| 2024-10-21 | -4.05 |
| 2024-10-18 | -4.23 |
| 2024-10-17 | -4.17 |
| 2024-10-16 | -4.45 |
| 2024-10-15 | -4.57 |
| 2024-10-14 | -4.49 |
| 2024-10-11 | -4.36 |
| 2024-10-10 | -4.20 |
| 2024-10-09 | -4.47 |
| 2024-10-08 | -4.30 |
| 2024-10-07 | -4.60 |
| 2024-10-04 | -4.81 |
| 2024-10-03 | -4.82 |
| 2024-10-02 | -4.91 |
| 2024-10-01 | -4.94 |